Lexicon Pharmaceuticals | LXRX - SCHULD





SCHULD Veränderung Datum
Abbott USD 34.05B 20.19B 2026-03
Acadia Pharmaceuticals USD 52.19M 2.62M 2025-12
Agios Pharmaceuticals USD 35.74M 4.46M 2026-03
Akebia Therapeutics USD 46.51M 7.82M 2025-03
Alnylam Pharmaceuticals USD 1.27B 5.33M 2026-03
AstraZeneca USD 33.92B 4.3B 2026-03
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Coherus Biosciences USD 294.92M 1.25M 2025-03
Eli Lilly USD 42.5B 3.6M 2025-12
Halozyme Therapeutics USD 2.14B 2.01M 2026-03
Illumina USD 2.54B 9M 2026-03
Insmed USD 727.62M 275K 2026-03
Ironwood Pharmaceuticals USD 583.99M 14.83M 2024-12
J&J USD 54.99B 7.05B 2026-03
Lexicon Pharmaceuticals USD 99.51M 243K 2023-12
MacroGenics USD 36.51M 500K 2026-03
MannKind USD 367.44M 247.53M 2025-12
Merck USD 49.34B 7.97B 2025-12
Moderna USD 1.31B 571M 2025-12
Novartis USD 49.01B 2.02B 2026-06
PTC Therapeutics USD 286.94M 2.42B 2026-03
Puma Biotechnology USD 89.06M 55.07M 2024-06
Sarepta Therapeutics USD 1.04B 210.44M 2025-12
Thermo Fisher Scientific USD 43.16B 3.78B 2026-03
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
United Therapeutics USD 200M 100M 2025-03
Vanda Pharmaceuticals USD 4.96M 4.96M 2024-12